Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk
- PMID: 28322904
- DOI: 10.1016/j.urology.2017.03.004
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
